辛伐他汀对一氧化氮缺乏性高血压大鼠心肌纤维化的作用1

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (4): 306-310.

辛伐他汀对一氧化氮缺乏性高血压大鼠心肌纤维化的作用¹

易春涛, 程晓曙, 俞建华, 鄢定红, 苏海, 吴清华

江西医学院第二附属医院心内科, 南昌 330006

收稿日期:2002-04-23 修回日期:2002-05-16 出版日期:2002-08-26 发布日期:2020-11-24
通讯作者: 易春涛, 男, 硕士, 副主任医师, 现在江西宜春市人民医院心内科( 336000) 。Tel:13006262638 Email:yict @163. com
作者简介:程晓曙, 男, 博士, 教授, 硕士生导师, 主要从事临床心血管病的研究。
基金资助:
1 本课题为江西省自然基金资助项目( №0100458)

Effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats

YI Chun-Tao, CHENG Xiao-Shu, YU Jian-Hua, YAN Ding-Hong, SU Hai, WU Qing-Hua

Department of Cardiology, The Second Affiliated Hospital of Jiangxi Medical College, Nanchang 33000

Received:2002-04-23 Revised:2002-05-16 Online:2002-08-26 Published:2020-11-24

摘要/Abstract

摘要： 目的: 观察辛伐他汀对一氧化氮( NO) 缺乏性高血压大鼠心肌纤维化的作用。方法: 24 只WKY 大鼠随机分为正常对照组( C 组) 、硝基精氨酸甲酯( LNAME)组( L 组) 和L-NAME +辛伐他汀组( L +S组), 8 wk 后测定大鼠血清和心肌组织血管紧张素Ⅱ( Ang Ⅱ) 、血管紧张素转换酶(ACE) 活性和心肌组织羟脯氨酸浓度, 并取大鼠左心室心肌横截面组织作病理形态检测和计算机图象分析。结果: L 组大鼠血浆ACE 活性与C 组相比明显降低( P <0. 01), 心肌ACE 活性则较C 组明显增高( P <0. 01), 辛伐他汀干预后血浆ACE 活性升高, 但与L 组无显著差异( P >0. 05), 心肌ACE 活性则比L 组有明显降低( P <0. 05); 各实验组大鼠血浆Ang Ⅱ水平与C 组比较未显示统计学差异( P >0. 05); L 组心肌组织AngⅡ水平与C 组比较显著增加( P <0. 01), L +S 组心肌组织Ang Ⅱ水平则较L 组明显降低( P <0. 05); 此外, L 组心肌羟脯氨酸浓度和左心室胶原容积分数(CVF) 和心肌内血管周围胶原面积( PVCA) 均比C组明显增高( P <0. 01), L +S 组羟脯氨酸浓度和CVF 、PVCA 值则均较L 组明显降低( P <0. 05) 。结论: 辛伐他汀可能通过降低局部心肌组织ACE 活性减少Ang Ⅱ生成, 减轻心肌纤维化。

关键词: 辛伐他汀, 心肌纤维化, 血管紧张素Ⅱ, 血管紧张素转换酶, 高血压

Abstract: AIM: To investigate the effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats. METHODS: Twenty-four male Wistar-Kyoto rats were divided into three groups: Control ( C) group, L-NAME ( L) group, and L-NAME plus Simvastatin ( L +S) group. The levels of ACE and Ang Ⅱ in plasma and myocardial tissue, and the contents of hydroxyproline concentration in myocardial tissue were measured after 8 weeks. The values of CVF, PVCA and the hydroproline concentration ( HC ) were studied using the methods of pathological examination combined with computed processing. RESULTS: The activity of ACE in serum in L group was lower than that in C group ( P <0. 01). Simvastatin treatment did not significantly increase the activity of ACE compared with L group ( P >0. 05). However, the activity of ACE in myocardial tissue was lower than that of C group ( P <0. 05). Although the levels of Ang Ⅱ in plasma were not altered by L-NAME ( P >0. 05), the concentrations of Ang Ⅱ in myocardial tissue ( P < 0. 01) were significantly increased in L group compared to C group. Simvastatin significantly decreased the levels of Ang Ⅱ in myocardial tissue ( P <0. 05). The hydroxyproline concentration and the value of PVCA and CVF in L group were significantly higher than that in C group ( P <0. 01), which were significantly attenuated by simvastatin tratment ( P <0. 05). CONCLUSION: Simvastatin may decrease the production of Ang Ⅱ and attenuate myocardial fibrosis via reducing the activity of ACE in NOdeficient hypertensive rats.

Key words: simvastatin, angiotensin Ⅱ, myocardial fibrosis, angiotensin-converting enzyme, hypertension, NOS inhibitor

中图分类号:

R971
R965

易春涛, 程晓曙, 俞建华, 鄢定红, 苏海, 吴清华. 辛伐他汀对一氧化氮缺乏性高血压大鼠心肌纤维化的作用¹[J]. 中国临床药理学与治疗学, 2002, 7(4): 306-310.

YI Chun-Tao, CHENG Xiao-Shu, YU Jian-Hua, YAN Ding-Hong, SU Hai, WU Qing-Hua. Effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 306-310.

参考文献

1 Takewakis S, Kuro-o M, Hiroi Y, et al. Activation of Na⁺- H⁺ antiporter ( NHE-1) gene expression during growth hypertrophy and proliferation of the rabbit cardiovascular system[J]. J Mol Cell Cardiol, 1995;27: 729-42
2 Weber KT, Brilla CG, Janicki JS.Myocardial fibrosis functional significance and regulatory factors[J]. Cardiovasc Res, 1993; 27: 341-7
3 Davignon J, Laaksonen R.Low-density lipoprotein-independent effects of statins[J]. Curr Opin Lipodol, 1999;10: 543
4 Oi S, Haneda J, Osaki J, et al. Lovastatin prevents angiotensin Ⅱ-induced cardiac hypertrophy in cultured neonatal rat heart cells[J]. Eur J pharmacol, 1999;376:139-46
5 Brilla CG.Renin-angiotensin-aldosterone system and myocardial fibrosis[J]. Cardiovasc Res, 2000;47:1-3
6 Sadoshima J, Izumo S.Molecular charac-terization of angiotensin Ⅱ-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts.Critical role of the AT1 receptor subtype[J]. Cir Res, 1993; 73:413-8
7 Unger T, Ganten D, Lang RE, et al. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin Ⅱ: therapeatic implication[J]. Am J Cardiol, 1987;59: 18D-22D
8 Kobayashi N, Hara K, Watanabe S, et al. Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA[J]. Am J Hypertens, 2000;13: 199-207
9 Henrion D, Dechaux Em, Dowell FJ, et al. Alteration of flowinduced dilataration in mesenreric resistance arteries of L-NAME treated rats and its partial association with induction of cyclooxygenase- 2[J]. Br J Pharmacol, 1997; 121:83-90
10 易春涛, 程晓曙, 俞建华, 等.辛伐他汀对一氧化氮缺乏性高血压大鼠心脏局部肾素血管紧张素系统的影响.中国临床药理学与治疗学[J]. 2002;7: 227-30
11 Ohta K, Kims S, Wanibuchi D, et al. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR( mRen2) 27 transgenic rats [J]. Circulation, 1996; 94:785-91
12 Chih-chang W, Meng QC, Palmer R, et al. Evidence for Angiotensin- converting enzyme- and chymase-mediated angiotensin Ⅱ formation in the interstitial fluid space of the dog heart in vivo[J]. Circulation, 1999;99:2583-9
13 Mitani H, Bandoh T, Ishikawa J, et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits[J]. Br J Pharmacol, 1996;119:1269-75
14 Takewakis S, Kuro-o M, Hiroi Y, et al. Activation of Na⁺- H⁺ antiporter ( NHE-1) gene expression during growth, hypertrophy and proliferation oftherabbitcardiovascular system[J]. J Mol Cell Cardiol, 1995; 27:729-42

[1]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[2]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[3]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[4]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[5]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[6]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[7]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[8]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[9]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[10]	牛丕莲, 范永鑫, 路富瑞, 周学章, 白明生. 甘草提取物对TGF-β1诱导心肌成纤维细胞纤维化的影响[J]. 中国临床药理学与治疗学, 2022, 27(2): 129-135.
[11]	贾成文, 蒋虎刚, 高翔, 韩金晏, 徐晓东, 赵信科. 当归红芪超滤物对miR-21-5P靶向调控TGF-β1介导放射性心肌纤维化的干预效应[J]. 中国临床药理学与治疗学, 2022, 27(11): 1221-1230.
[12]	汤佳卫, 孟祥哲, 孙学敏, 李玥轩, 刘雪, 魏红. 维生素D与ACE2在COVID-19中的作用[J]. 中国临床药理学与治疗学, 2022, 27(11): 1292-1298.
[13]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[14]	叶鹏, 谭兴, 冷岳奇, 王杨凯, 王伟忠. 基于交感神经系统的高血压非药物治疗研究现状和进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1335-1343.
[15]	赵玮, 吴悠扬, 林丛, 黄时伟, 陈皓, 姜文兵. 紫檀芪对急性心肌梗死大鼠心肌功能、心肌纤维化和炎症反应的作用及对Notch1/eIF3a信号通路的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 498-504.

辛伐他汀对一氧化氮缺乏性高血压大鼠心肌纤维化的作用¹

Effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价